(R)-Lorazepam

(R)-Lorazepam

SCHEMBL26962

O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=N[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ

The experimentally established mechanism targets of (R)-Lorazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP known ✓ O00591 1/20 0.58
GABRD known ✓ O14764 1/20 0.58
GABRA1 known ✓ P14867 1/20 0.58
GABRB1 known ✓ P18505 1/20 0.58
GABRG2 known ✓ P18507 1/20 0.58
GABRB3 known ✓ P28472 1/20 0.58
GABRA5 known ✓ P31644 1/20 0.58
GABRA3 known ✓ P34903 1/20 0.58
GABRA2 known ✓ P47869 1/20 0.58
GABRB2 known ✓ P47870 1/20 0.58
GABRA4 known ✓ P48169 1/20 0.58
GABRE known ✓ P78334 1/20 0.58
GABRA6 known ✓ Q16445 1/20 0.58
GABRG1 known ✓ Q8N1C3 1/20 0.58
GABRG3 known ✓ Q99928 1/20 0.58
GABRQ known ✓ Q9UN88 1/20 0.58
LMNA P02545 2/20 1.00
PGR P06401 1/20 1.00
MEN1 O00255 1/20 0.75
ALB P02768 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lorazepam SCHEMBL5271784 1.00 LMNA (1.00) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL29516559 1.00 LMNA (1.00) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL29388543 1.00 LMNA (1.00) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL29358033 1.00 LMNA (1.00) LMNAPGRMEN1ALBKMT2A
(S)-Lorazepam SCHEMBL120031 1.00 LMNA (1.00) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL13747464 1.00 LMNA (1.00) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL26961 1.00 LMNA (1.00) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL28931472 0.99 LMNA (0.97) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL5908139 0.99 LMNA (0.97) LMNAPGRMEN1ALBKMT2A
Lorazepam SCHEMBL6500339 0.99 LMNA (0.97) LMNAPGRMEN1ALBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 40411 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624037-B2 Method of treating agitation, aggressive behavior, and impulse control disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
US-12624036-B2 Method of treating post-traumatic stress disorder INTRA-CELLULAR THERAPIES, INC. (US) 2026-05-12 US claimed
US-12616653-B2 Solid orodispersible pharmaceutical composition in film containing lorazepam ALTERGON S.A. (CH) 2026-05-05 US claimed
US-20260115161-A1 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN LAMINAR PHARMACEUTICALS S A (ES) 2026-04-30 US claimed
WO-2026090360-A1 FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC. (US) 2026-04-30 WO claimed
US-20260108529-A1 FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC (US) 2026-04-23 US claimed
EP-4725506-A2 THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Stealth BioTherapeutics Inc. (US) 2026-04-15 EP claimed
US-12594256-B2 A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy ANAVEX LIFE SCIENCES CORP. (US) 2026-04-07 US claimed
US-12594388-B2 Device to deliver a predetermined amount of a substance to a natural orifice of the body APTARGROUP, INC. (US) 2026-04-07 US claimed
US-20260092932-A1 METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) 2026-04-02 US claimed
EP-0156592-A2 Substained release pharmaceutical capsules AMERICAN HOME PRODUCTS CORPORATION (US) 1985-10-02 EP claimed
WO-1985004100-A1 SUSTAINED RELEASE PHARMACEUTICAL CAPSULES AMERICAN HOME PRODUCTS CORPORATION (US) 1985-09-26 WO claimed
EP-0151245-A2 Soporific comprising lorazepam MEDICHEMIE AG (CH) 1985-08-14 EP claimed
EP-0110955-A1 BRAIN-SPECIFIC DRUG DELIVERY. UNIV FLORIDA (US) 1984-06-20 EP claimed
EP-0098113-A1 A combination of beta-adrenoceptor antagonists and anxiolytic agents AYERST, MCKENNA AND HARRISON INC. (CA) 1984-01-11 EP claimed
WO-1983003968-A1 BRAIN-SPECIFIC DRUG DELIVERY UNIVERSITY OF FLORIDA (US) 1983-11-24 WO claimed
US-4316897-A TRANQUILIZERS HOFFMANN-LA ROCHE INC. (US) 1982-02-23 US claimed
EP-0025546-A2 Therapeutical use of tranquillizing benzodiazepine derivatives and mixtures containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-03-25 EP claimed
US-4028466-A Analgesic compositions comprising dextro-propoxyphene and benzodiazepine and process BERGER FRANK M 1977-06-07 US claimed
US-4028467-A Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process BERGER FRANK M 1977-06-07 US claimed